EPCAM and ovarian cancer: We demonstrated that an increased expression of EpCAM in primary tumors was correlated with shortened overall and progression-free survival for patients with stage I–IV ovarian cancer, suggesting that EpCAM-positive cancer cells are responsible for poor prognosis with strong ability of chemoresistance.